COMPOUNDS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS

(19)

(11)

EP 3 684 418 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	19.03.2025 Bulletin 2025/12

(45)	Mention of the grant of the patent:
	12.02.2025 Bulletin 2025/07

(21)	Application number: 18858763.8

(22)	Date of filing: 20.09.2018

(51)

International Patent Classification (IPC):

A61K 31/145^(2006.01)
C07C 323/41^(2006.01)
A61K 31/164^(2006.01)
A61K 31/375^(2006.01)
A61P 25/00^(2006.01)

A61K 47/54^(2017.01)
C07H 15/203^(2006.01)
A61K 31/355^(2006.01)
A61K 45/06^(2006.01)
C07C 323/25^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	C07C 323/25; A61P 25/00; A61K 31/164; A61K 45/06; A61K 31/145; A61K 31/375; A61K 31/355

	C-Sets:
	A61K 31/145, A61K 2300/00; A61K 31/164, A61K 2300/00; A61K 31/375, A61K 2300/00; A61K 31/355, A61K 2300/00;

(86)	International application number:
	PCT/US2018/052080

(87)	International publication number:
	WO 2019/060634 (28.03.2019 Gazette 2019/13)

(54)	COMPOUNDS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS VERBINDUNGEN ZUR BEHANDLUNG VON CYSTEAMINEMPFINDLICHEN ERKRANKUNGEN COMPOSÉS POUR LE TRAITEMENT DES TROUBLES SENSIBLES À LA CYSTÉAMINE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

20.09.2017 US 201762561101 P

(43)	Date of publication of application:
	29.07.2020 Bulletin 2020/31

(60)	Divisional application:
	25157232.7

(73)	Proprietor: Thiogenesis Therapeutics, Inc.
	San Diego, CA 92130 (US)

(72)	Inventors:
	STANTON, Vincent, P., Jr. Belmont MA 02478 (US) RIOUX, Patrice, P. San Diego CA 92130 (US) BARSKI, Piotr PL-81-823 Sopot (PL) WITT, Dariusz PL-80-299 Gdansk (PL)

(74)	Representative: Kransell & Wennborg KB
	P.O. Box 27834 115 93 Stockholm 115 93 Stockholm (SE)

(56)

References cited: :

WO-A1-2017/161318
US-A1- 2003 176 359
US-A1- 2019 070 132

WO-A2-2014/087307
US-A1- 2012 277 305

AMORUSO D C ET AL: "OC3.04.3 THERAPEUTIC EFFECTS OF CYSTAMINE IN A MURINE MODEL OF LIVER FIBROSIS", DIGESTIVE AND LIVER DISEASE, W.B. SAUNDERS, GB, vol. 40, 1 March 2008 (2008-03-01), pages S46, XP022585399, ISSN: 1590-8658, [retrieved on 20080301], DOI: 10.1016/S1590-8658(08)60117-6
DATABASE PUBCHEM Compound [o] 16 June 2014 (2014-06-16), "YRMNURUCNHQQDL-NSHDSACASA-N | C13H27N3O4S2", XP055585147, retrieved from ncbi Database accession no. CID74539418


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).